EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era

Luani Barge iD, Steven Tran, Glen Kennedy, David Ritchie, David Gottlieb, Sam Milliken, Andrew Spencer, Duncan Purtill, Travis Perera, Richard Doocey, Stephen Larsen, Andrew Butler iD und 11 weitere

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Luani Barge und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Princess Alexandra Hospital University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukaemia Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic haemopoietic stem cell transplantation (HSCT) is an effective therapy with curative potential for patients with high‐risk or relapsed/refractory chronic lymphocytic leukaemia (CLL). There are limited data on the use and outcomes of HSCT in the modern era of CLL treatment.

Aims

The aim of this study was to examine the use of HSCT performed for CLL in Australia and New Zealand, including patients exposed to pathway inhibitors (PIs) prior to transplant.

Methods

Data were collected through the Australian and New Zealand Transplant and Cellular Therapy Registry for all patients who underwent HSCT for CLL between January 2009 and December 2018. Transplant outcomes were compared between two 5‐year time periods: 2009–2013 and 2014–2018.

Results

Ninety‐four patients underwent HSCT during 2009–2013 and 50 during 2014–2018. There was a significant reduction in non‐relapse mortality (NRM) from 42% (95% confidence interval (CI): 31–52) to 23% (95% CI: 12–35, P = 0.02) between the periods; however, overall survival (OS), progression‐free survival (PFS) and relapse were unchanged. Within the 2014–2018 cohort, 22 patients were PI exposed prior to transplant. At 3 years, these patients demonstrated a median OS of 54% (95% CI: 35–82), PFS of 44% (95% CI: 27–71), NRM of 25% (95% CI: 8–45) and cumulative incidence of relapse of 32% (95% CI: 14–52). In multivariate analysis, only disease in complete remission at the time of HSCT was associated with improved OS (hazard ratio: 2.54, 95% CI: 1.04–6.18).

Conclusion

Allogeneic HSCT remains a viable treatment option for select patients with CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHematopoietic Stem Cell TransplantationHumansMaleFemaleMiddle AgedAgedAustraliaNew ZealandTransplantation, HomologousTreatment OutcomeAdultRetrospective StudiesRegistries

Stichwörter der Autor:innen

BCL2 inhibitorBruton tyrosine kinase inhibitorallogeneic haemopoietic stem cell transplantationchronic lymphocytic leukaemiapathway inhibitor

Autor:innen und Institutionen

  • Department of Haematology, Princess Alexandra Hospital University of Queensland, Brisbane, Queensland, Australia.
  • Department of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  • Department of Haematology, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Queensland, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Haematology, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Haematology, The Alfred, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Luani Barge, Andrew Butler, Matthew Greenwood, Constantine Tam, Pietro R Di Ciaccio, Nada Hamad

Förderung

  • Leukaemia Foundation

Zitieren

APA

Barge, L., Tran, S., Kennedy, G., Ritchie, D., Gottlieb, D., Milliken, S., Spencer, A., Purtill, D., Perera, T., Doocey, R., Larsen, S., Butler, A., Bardy, P., Greenwood, M., Durrant, S., Curley, C., Stewart, C., Tam, C., Balendran, S., …, & Hamad, N. (2025). Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era. Internal Medicine Journal. https://doi.org/10.1111/imj.70050

Vancouver

Barge L, Tran S, Kennedy G, Ritchie D, Gottlieb D, Milliken S, et al. Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era. Internal Medicine Journal. 2025. doi:10.1111/imj.70050

BibTeX
@article{Barge2025,
  author = {Barge, Luani and Tran, Steven and Kennedy, Glen and Ritchie, David and Gottlieb, David and Milliken, Sam and Spencer, Andrew and Purtill, Duncan and Perera, Travis and Doocey, Richard and Larsen, Stephen and Butler, Andrew and Bardy, Peter and Greenwood, Matthew and Durrant, Simon and Curley, Cameron and Stewart, Caroline and Tam, Constantine and Balendran, Shalini and Di Ciaccio, Pietro R and Patil, Sushrut and Han, Min-Hi and Hamad, Nada},
  title = {Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70050}
}
Kostenlos starten →